Drugs / 177Lu-DOTA-SNA040
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07595237 | Nov 2025 overdue | cholangiocarcinoma, gastric cancer, gastroesophageal junction adenocarcinoma, malignant pancreatic neoplasm | SmartNuclide Biopharma | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-DOTA-SNA040 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07595237 ↗ |